Journal profile · ONCOLOGY-IMMUNOLOGY
OncoImmunology
ISSN 2162-4011 · eISSN 2162-402X · Landes Bioscience · UNITED STATES
OncoImmunology: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 6.16; fully open access; APC about USD 2,913; review about 24 weeks (community reports); 120 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
OncoImmunology is published by Landes Bioscience and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses and Immune Cell Function and Interaction, together about 51.3% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Taylor & Francis publishes knowledge and specialty research spanning humanities, social sciences, science and technology, engineering, medicine and healthcare.
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY-IMMUNOLOGY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine18.6%
- Immunotherapy and Immune ResponsesImmunology and Microbiology17.4%
- Immune Cell Function and InteractionImmunology and Microbiology15.3%
- CAR-T cell therapy researchMedicine11.2%
- Immune cells in cancerImmunology and Microbiology7.8%
- T-cell and B-cell ImmunologyImmunology and Microbiology5.7%
- Virus-based gene therapy researchBiochemistry, Genetics and Molecular Biology2.2%
- Monoclonal and Polyclonal Antibodies ResearchMedicine2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Immunology | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
| Minor | Immunology | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Immunology | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.16LetPub ·
- CiteScore 2026-06
- 12.1LetPub ·
- SJR 2026-06
- 2.44LetPub ·
- SNIP 2026-06
- 1.1LetPub ·
- h-index
- 58LetPub ·
- h-index
- 154OpenAlex ·
- i10-index
- 3,025OpenAlex ·
- 2-year mean citedness
- 6.4OpenAlex ·
- Self-citation rate
- 1.6%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 116LetPub ·
Articles by year OpenAlex count · 3,918 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 84 | 84 | 64 |
| 2025 | 120 | 120 | 682 |
| 2024 | 119 | 119 | 1,320 |
| 2023 | 129 | 129 | 2,186 |
| 2022 | 194 | 194 | 5,674 |
| 2021 | 234 | 234 | 8,062 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- about 24 weeksLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | GBP 2,375 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Landes Bioscience
- Country or region
- UNITED STATES
- Language
- English
- ISSN
- 2162-4011
- Electronic ISSN
- 2162-402X
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about OncoImmunology
What CAS zone is OncoImmunology in?
In the 2025 upgraded edition of the CAS Journal Ranking, OncoImmunology is in Zone 2 of Medicine, and in Zone 2 of the minor category Immunology / Oncology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of OncoImmunology?
The latest impact factor listed by LetPub is 6.16; CiteScore 12.1, h-index 154.
How long does peer review take at OncoImmunology?
Authors report an average review time of about 24 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index OncoImmunology?
According to LetPub and DOAJ records, OncoImmunology is indexed in SCIE, Scopus and DOAJ.
Is OncoImmunology open access, and what is the APC?
OncoImmunology is a fully open-access journal. APC about USD 2,913.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .